These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Chronic inflammatory demyelinating polyradiculoneuropathy and multifocal motor neuropathy: treatment update. Nobile-Orazio E; Gallia F; Tuccillo F; Terenghi F Curr Opin Neurol; 2010 Oct; 23(5):519-23. PubMed ID: 20689427 [TBL] [Abstract][Full Text] [Related]
8. Subcutaneous immunoglobulin in CIDP and MMN: a different long-term clinical response? Cocito D; Merola A; Romagnolo A; Peci E; Toscano A; Mazzeo A; Gentile L; Russo M; Fazio R; Filosto M; Siciliano G; Schirinzi E; Nobile-Orazio E; Lopiano L J Neurol Neurosurg Psychiatry; 2016 Jul; 87(7):791-3. PubMed ID: 26109674 [No Abstract] [Full Text] [Related]
9. Complications of Immunoglobulin Therapy and Implications for Treatment of Inflammatory Neuropathy: A Review. Abbas A; Rajabally YA Curr Drug Saf; 2019; 14(1):3-13. PubMed ID: 30332974 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin treatment in CIDP and MMN. Efficacy, treatment satisfaction and costs. Markvardsen LH; Harbo T J Neurol Sci; 2017 Jul; 378():19-25. PubMed ID: 28566163 [TBL] [Abstract][Full Text] [Related]
11. Subcutaneous immunoglobulin infusion: a new therapeutic option in chronic inflammatory demyelinating polyneuropathy. Lee DH; Linker RA; Paulus W; Schneider-Gold C; Chan A; Gold R Muscle Nerve; 2008 Mar; 37(3):406-9. PubMed ID: 17918749 [TBL] [Abstract][Full Text] [Related]
12. Systematic reviews of treatment for chronic inflammatory demyelinating neuropathy. Hughes RA Rev Neurol (Paris); 2002 Dec; 158(12 Pt 2):S32-6. PubMed ID: 12690659 [TBL] [Abstract][Full Text] [Related]
13. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. Markvardsen LH; Christiansen I; Jakobsen J Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495 [TBL] [Abstract][Full Text] [Related]
14. Quality of life in chronic inflammatory demyelinating polyneuropathy patients treated with subcutaneous immunoglobulin. Ryltoft AK; Al-Zuhairy A; Sindrup SH; Andersen H; Markvardsen LK Acta Neurol Scand; 2020 Dec; 142(6):637-640. PubMed ID: 33404110 [TBL] [Abstract][Full Text] [Related]
16. Intravenous immunoglobulin is effective in patients with diabetes and with chronic inflammatory demyelinating polyneuropathy: long term follow-up. Jann S; Bramerio MA; Facchetti D; Sterzi R J Neurol Neurosurg Psychiatry; 2009 Jan; 80(1):70-3. PubMed ID: 18768571 [TBL] [Abstract][Full Text] [Related]
17. Intravenous immunoglobulin for treatment of chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy in France: are daily practices in accordance with guidelines? Rosier C; Graveline N; Lacour A; Antoine JC; Camdessanché JP Eur J Neurol; 2019 Apr; 26(4):575-580. PubMed ID: 30326184 [TBL] [Abstract][Full Text] [Related]
18. Update on therapy of chronic immune-mediated neuropathies. Briani C; Cocito D; Campagnolo M; Doneddu PE; Nobile-Orazio E Neurol Sci; 2022 Dec; 43(Suppl 2):605-614. PubMed ID: 33452933 [TBL] [Abstract][Full Text] [Related]